Kathleen B Orrico

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Caring for visually impaired patients
    Kathleen B Orrico
    Palo Alto Medical Foundation, 795 El Camino Real Pharmacy Level A, Palo Alto, CA 94301, USA
    J Am Pharm Assoc (2003) 53:e142-50. 2013
  2. ncbi request reprint Sources and types of discrepancies between electronic medical records and actual outpatient medication use
    Kathleen B Orrico
    University of California, San Francisco, School of Pharmacy, USA
    J Manag Care Pharm 14:626-31. 2008
  3. ncbi request reprint Clinical consequences of disseminating the rosiglitazone FDA safety warning
    Kathleen B Orrico
    School of Pharmacy, University of California, San Francisco, USA
    Am J Manag Care 16:e111-6. 2010
  4. ncbi request reprint Assessment of the appropriateness of serum digoxin concentration measurement in a medical group setting
    Kathleen B Orrico
    School of Pharmacy, University of California, San Francisco, USA
    J Manag Care Pharm 17:695-700. 2011

Detail Information

Publications4

  1. doi request reprint Caring for visually impaired patients
    Kathleen B Orrico
    Palo Alto Medical Foundation, 795 El Camino Real Pharmacy Level A, Palo Alto, CA 94301, USA
    J Am Pharm Assoc (2003) 53:e142-50. 2013
    ..To raise pharmacist awareness about the needs and concerns of our patients with visual impairment and to review useful strategies to foster medication adherence...
  2. ncbi request reprint Sources and types of discrepancies between electronic medical records and actual outpatient medication use
    Kathleen B Orrico
    University of California, San Francisco, School of Pharmacy, USA
    J Manag Care Pharm 14:626-31. 2008
    ..Classifying discrepancies between the electronic medical record (EMR) and actual drug use by the root cause of discrepancy (either system generated or patient generated) would guide quality improvement initiatives...
  3. ncbi request reprint Clinical consequences of disseminating the rosiglitazone FDA safety warning
    Kathleen B Orrico
    School of Pharmacy, University of California, San Francisco, USA
    Am J Manag Care 16:e111-6. 2010
    ....
  4. ncbi request reprint Assessment of the appropriateness of serum digoxin concentration measurement in a medical group setting
    Kathleen B Orrico
    School of Pharmacy, University of California, San Francisco, USA
    J Manag Care Pharm 17:695-700. 2011
    ..Several studies have shown that the majority of the SDCs obtained in hospital settings provide little clinically actionable information...